how long can you be on a glp-1 Why Microdosing? Closer Look at Reported Benefits How Long Can You Take

When examining a composite cardio outcomes endpoint (death from CV disease, nonfatal myocardial infarction, nonfatal stroke, or hospitalization for unstable angina), the ELIXA trial suggested that GLP-1s did not increase cardiovascular event risk (hazard ratio of 1.02)

Tirzepatide has been associated with an increased risk of gallstones and cholecystitis

Your doctor will guide you about the dosing schedule

How is my weight trending

[Google Scholar] Davies M, STEP 2 Study Group, Frch L, Jeppesen OK, Pakseresht A, Pedersen SD, Perreault L, Rosenstock J, Shimomura I, Viljoen A, Wadden TA et al

Confirming a program's pharmacy type is a direct way to assess how it operates